ONA, OTCQBNANF) announced that it has dosed the first patient in an early feasibility study of its Targeted Hyperthermia Therapy (THT) cancer treatment. The study is evaluating the safety, tolerability, and preliminary efficacy of its THT therapy in patients with advanced melanoma who have not responded to standard immunotherapy treatments. 